Venus Remedies
759.35
-11.45(-1.49%)
Market Cap₹1,015.02 Cr
PE Ratio13.49
IndustryHealthcare
Company Performance:
1D-1.49%
1M-0.15%
6M+56.89%
1Y+145.90%
5Y+240.59%
View Company Insightsright
More news about Venus Remedies
08Jan 26
Venus Remedies gets Indonesia nod for antibiotic combo Ceftazidime + Avibactam
Venus Remedies Limited has secured marketing authorisation from Indonesian drug regulatory authorities for its antibiotic combination Ceftazidime + Avibactam, representing the first approval for this specific product in Indonesia. The approved combination targets serious infections caused by multi-drug resistant gram-negative pathogens, specifically complicated intra-abdominal and urinary tract infections, positioning the company to address critical healthcare needs in one of Southeast Asia's largest pharmaceutical markets.
 no imag found
08Dec 25
Venus Remedies Secures ₹11 Crore Final Milestone Payment from Cipla for AMR Drug
Venus Remedies has received the final milestone payment of ₹11 crore from Cipla Ltd, completing their 2019 licensing agreement for an innovative anti-infective drug in India. The patented product, developed by Venus Medicine Research Centre, has benefited over one million patients targeting multidrug-resistant infections. No serious drug-related adverse events have been reported in post-marketing experience. This achievement marks the successful completion of all commercial milestones for the Indian territory and underscores Venus Remedies' commitment to combating Antimicrobial Resistance.
 no imag found
01Dec 25
Venus Remedies Eliminates ₹33.44 Crore Contingent Liability, Resolves Income Tax Matters
Venus Remedies Limited has successfully resolved all pending Income Tax matters from earlier assessment years. The company has eliminated a contingent liability of ₹33.44 crores related to Income Tax. All outstanding tax demands have been fully resolved, and amounts previously deposited under protest have been refunded with applicable interest. This resolution is expected to positively impact the company's financial statements, potentially improving its financial stability and investor confidence.
 no imag found
10Nov 25
Venus Remedies Reports 40.5% Revenue Growth in Q2 FY26 Despite Subsidiary Challenges
Venus Remedies Limited announced impressive Q2 FY2026 results, with consolidated revenue reaching ₹192.75 crore, up 40.5% quarter-over-quarter. Net profit surged 109.7% to ₹20.13 crore. Half-year revenue stood at ₹329.93 crore with a net profit of ₹29.73 crore. The company's German subsidiary, Venus Pharma GmbH, reported a negative net worth but showed revenue of ₹10.61 crore and a net profit of ₹1.21 crore for the quarter. Management expects the subsidiary's financial position to improve by the end of FY2025-26.
 no imag found
27Aug 25
Venus Remedies Opens Special Window for Physical Share Transfer Re-lodgement
Venus Remedies announces a special window for re-lodgement of transfer requests for physical shares, in compliance with a recent SEBI circular. The company has shared this information on various social media platforms, providing an opportunity for shareholders with physical certificates to address pending transfer issues. This move aligns with SEBI's regulations and aims to facilitate the share transfer process.
 no imag found
01Aug 25
Venus Remedies Reports Stellar Q1 Performance with 8-Fold Surge in Net Profit
Venus Remedies Limited announced impressive Q1 results, with consolidated net profit soaring 687% year-over-year to ₹9.60 crore. Revenue from operations increased by 21.4% to ₹131.90 crore. EBITDA grew 46.3% to ₹18.80 crore. The company's EPS rose to ₹7.18 from ₹0.92. Venus Pharma GmbH, a wholly-owned subsidiary, faced challenges with eroded net worth, but management expects improvement. Venus Remedies operates solely in the 'Pharmaceuticals' segment.
 no imag found
27May 25
Venus Remedies Doubles Q4 Net Profit, Revenue Holds Steady
Venus Remedies reported a 100% increase in Q4 consolidated net profit, reaching ₹210.00 million, up from ₹105.00 million year-over-year. Revenue remained stable at ₹1.95 billion. The profit also improved quarter-over-quarter from ₹196.00 million. This significant profit growth without revenue increase suggests improved operational efficiency or successful cost-cutting measures.
 no imag found
26May 25
Venus Remedies Reports Strong Q4 Performance with Doubled Net Profit
Venus Remedies announced impressive Q4 results with net profit doubling to ₹210.00 crore, a 100% year-over-year increase. EBITDA rose by 48.79% to ₹290.00 crore, with the EBITDA margin improving to 14.87%. Revenue remained stable at ₹195.00 crore. For the full financial year, the company reported an 8.34% increase in revenue to ₹613.00 crore and a 7.14% rise in net profit to ₹28.50 crore.
 no imag found
22May 25
Venus Remedies Bolsters Global Presence with Ukrainian GMP Certification Renewal
Venus Remedies has successfully renewed its Good Manufacturing Practice (GMP) certification from Ukraine, ensuring continued operations and expansion in the Ukrainian market. This renewal validates the company's high-quality manufacturing standards, compliance with Ukrainian regulations, and facilitates ongoing access to the country's pharmaceutical market. The certification is strategically important for Venus Remedies, allowing market continuity, quality assurance, and a competitive edge in Ukraine. This development aligns with the company's global expansion strategy and commitment to international quality standards.
 no imag found
17Apr 25
Venus Remedies' Novel Antibiotic Formulation Receives FDA's QIDP Designation
Venus Remedies Limited's investigational product VRP-034 has received Qualified Infectious Disease Product (QIDP) designation from the US FDA for treating bloodstream infections. VRP-034 is a novel supramolecular cationic formulation of polymyxin B sulphate designed to reduce nephrotoxicity while maintaining efficacy. The QIDP status offers benefits like priority review, fast track eligibility, and extended market exclusivity. Preclinical studies show up to 70% reduction in nephrotoxicity compared to existing polymyxin B treatments, with robust efficacy against resistant pathogens.
 no imag found
25Feb 25
Venus Remedies Secures Exclusive Rights for MET-X: A Potential Game-Changer in Fighting Antibiotic Resistance
Venus Remedies Limited has entered an exclusive license agreement with UK-based Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, in India. MET-X, designed to combat drug-resistant Gram-negative bacteria, will be initially combined with meropenem. The company plans to conduct Phase I trials in India, followed by Phase II/III trials for complicated urinary tract infections. This agreement addresses a critical need in India, where meropenem resistance is high and no approved MBL inhibitors exist. The development will adhere to international standards, potentially supporting global commercialization efforts.
 no imag found
Venus Remedies
759.35
-11.45
(-1.49%)
1 Year Returns:+145.90%
Industry Peers
Sun Pharmaceutical
1,724.40
(+0.64%)
Divis Laboratories
6,291.00
(-0.10%)
Torrent Pharmaceuticals
4,241.70
(+0.36%)
Cipla
1,341.10
(+0.92%)
Dr Reddys Laboratories
1,280.40
(-0.15%)
Lupin
2,219.40
(-0.42%)
Zydus Life Science
900.75
(-0.18%)
Mankind Pharma
2,024.30
(-0.75%)
Aurobindo Pharma
1,158.80
(-1.08%)
Alkem Laboratories
5,392.00
(+0.28%)